The Financial Times pegs the rumored price at around $10 billion.
Me? I’d be surprised, but never say never. Here’s a bit on it:
…The deal would value Verona at $107 per American depositary share, the report said, citing three sources familiar with the negotiations. That represents a 23% premium to its Tuesday’s closing price.
Verona Pharma is focused on developing and commercializing therapies for the treatment of chronic respiratory diseases (COPD), with Ohtuvayre (ensifentrine) its first commercial product….
Yep… dead Midsummer days seem to spawn the occasional deal rumor. Onward. It will, of course, complement the Winrevair™ franchise….
But what of Trump’s new threat to charge non-US pharma a 200% price tariff for importing to the US?! How can one defend this price, if the corrupt clown persists in his… lunacy?!
नमस्ते
Powerline Lies... 